Tolerability of montelukast

Area of Science:

• Pediatric Pharmacology
• Respiratory Medicine
• Clinical Therapeutics

Background:

• Medication tolerability in pediatric asthma is crucial, influenced by efficacy, side effects, dosing, administration, and taste.
• Montelukast's pediatric license was granted concurrently with the adult license, supported by extensive safety and efficacy data.

Purpose of the Study:

• To evaluate the overall tolerability and safety profile of montelukast in pediatric asthma patients.
• To assess key factors contributing to medication adherence and acceptance in children.

Main Methods:

• Review of pharmacological data, adult and pediatric clinical studies, and post-marketing surveillance data.
• Analysis of adverse event rates compared to placebo and inhaled corticosteroids.
• Examination of prescribing databases for drug discontinuation rates in children.

Main Results:

• Montelukast demonstrated a tolerability profile similar to placebo and inhaled corticosteroids in pediatric studies.
• Common adverse effects (headache, asthma, upper respiratory tract infection) were not significantly different from placebo.
• Low discontinuation rates (<25% in the UK) suggest good tolerability and effectiveness in children.

Conclusions:

• Montelukast is generally well-tolerated in children with asthma, supported by its clinical effectiveness, safety profile, and convenient administration.
• The oral route, once-daily dosing, and palatability enhance montelukast's suitability for pediatric use.
• While Churg-Strauss syndrome has been linked to montelukast in adults (often with corticosteroid withdrawal), it has not been reported in children.